Quarterly ResultMay 4, 2026, 04:14 PM
Biohaven Q1 Net Loss Narrows to $130.5M; Advances Pipeline
AI Summary
Biohaven Ltd. reported a net loss of $130.5 million, or $0.88 per share, for the first quarter ended March 31, 2026, a significant reduction from $221.7 million, or $2.17 per share, in the prior year period. The company also highlighted substantial progress in its clinical pipeline, including the expected mid-year initiation of pivotal trials for BHV-1400 in IgA nephropathy and BHV-1300 in Graves' disease. Additionally, topline results for its pivotal epilepsy program and Phase 2 obesity study are anticipated in the second half of 2026.
Key Highlights
- Net loss for Q1 2026 was $130.5 million, or $0.88 per share, compared to $221.7 million, or $2.17 per share, in Q1 2025.
- Non-GAAP adjusted net loss was $102.2 million, or $0.69 per share, for Q1 2026.
- Research and Development (R&D) expenses decreased to $103.8 million in Q1 2026 from $187.6 million in Q1 2025.
- General and Administrative (G&A) expenses decreased to $26.6 million in Q1 2026 from $34.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled approximately $351.8 million as of March 31, 2026.
- Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) are expected to initiate by mid-year 2026.
- Topline results for the pivotal epilepsy program and Phase 2 obesity study are expected in 2H 2026.